Igg1 fc mutants with ablated effector functions

A molecular and carrier technology, applied in the field of IgG1 Fc mutants whose effector function is eliminated, can solve the problems of reducing FcγR binding and identifying mutations

Pending Publication Date: 2020-08-04
CILAG GMBH INT
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] However, the challenge remains to identify combinations of mutations that result in an optimal reduction of FcγR binding and, importantly, do not negatively affect other key properties important to the drug product, such as processability, pharmacokinetics or antigenicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Igg1 fc mutants with ablated effector functions
  • Igg1 fc mutants with ablated effector functions
  • Igg1 fc mutants with ablated effector functions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0180] 1. A recombinant IgG1 Fc-containing molecule comprising a CH2 domain in which the amino acid at position 265 is different from aspartic acid (D), position 297 The amino acid at position 329 is different from asparagine (N), the amino acid at position 329 is different from proline (P), where the numbering is indicated by the EU index in Kabat.

[0181] 2. The molecule of embodiment 1, wherein said molecule has, compared to an IgG1 Fc-containing molecule having a wild-type CH2 domain comprising D at position 265, N at position 297, and P at position 329, Reduced binding to C1q and to at least one Fcγ receptor (FcγR).

[0182] 3. The molecule of embodiment 1 or 2, wherein said molecule retains binding to FcRn.

[0183] 4. The molecule of any one of embodiments 2-3, wherein at least one FcyR is FcyRI, FcyRIIa, FcyRIIb, FcyRIIIa, and FcyRIIIb.

[0184] 5. The molecule of any one of embodiments 1-4, wherein

[0185] i. the amino acid at position 265 is alanine (A), asparag...

example

[0217] The following examples are provided to supplement the existing disclosure and provide a better understanding of the subject matter described herein. These examples should not be viewed as limiting the described subject matter. It should be understood that the examples and embodiments described herein are for illustrative purposes only, and that various modifications or changes therefrom will be apparent to those skilled in the art and are to be included therein and can be made without departing from this document. made without the scope of the invention.

example 1

[0218] Example 1. Expression and purification of Fc mutated antibodies

[0219] Several antibodies with different mutations in the CH2 domain were produced based on mAb1 (mAb1 is a human IgG1 antibody specific for human CD3). The mutations are:

[0220] -i) N297A,

[0221] -ii) D265 plus P329A (DAPA),

[0222] -iii) D265 plus N297A plus P329A (DANAPA), and

[0223] -iv) L234A plus L235A (LALA)

[0224] (EU numbering according to Kabat (Kabat, E.A. (1991). Sequences of proteins of immunological interest [ Protein sequences of immunological significance], Bethesda, MD: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1991).

[0225] For expression of antibodies, a leader sequence is usually present, which is excised and no longer present in the secreted product. An example of a leader sequence for expression in the examples described herein is provided in SEQ ID NO:42, and an example of a nucleotide sequence encoding the l...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

An antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to C1q and Fc gamma receptors are provided, which can be used in the treatment of various diseases and disorders.

Description

technical field [0001] The disclosure provided herein relates to mutated human antibody IgGl constant regions (Fc regions) such that they retain FcRn binding but substantially lose the ability to specifically bind Fcγ receptors and CIq. Background technique [0002] Immunoglobulin is a glycoprotein present in the serum, tissue or body fluid of every mammal, and has the function of recognizing foreign antigens. Immunoglobulins either through activation of the complement system by antibody-binding antigens or through activation of effector functions such as enhanced phagocytosis, antibody-dependent cytotoxicity, and activation induced by interaction with Fc receptors (FcRs) present on the surface of effector cells Mediator release) participate in biological defense. [0003] Human immunoglobulins are divided into 5 different classes IgG, IgA, IgM, IgD and IgE. IgG can be further divided into four subclasses consisting of IgGl, IgG2, IgG3 and IgG4, while IgA can be further di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C07K16/32
CPCC07K16/32C07K2317/41C07K2317/94C07K16/2818A61K2039/505C07K2317/24C07K2317/70C07K2318/20C07K16/2809C07K16/2803C07K2317/524C07K2317/21C07K2319/30C07K2317/71C07K2317/92C07K2317/76C07K2317/31C07K16/28C12N5/10C12N15/63A61K39/395C07K2317/52C07K2317/732C07K2317/734C07K2317/14
Inventor S·S·布拉克I·阿廷杰-托勒F·布勒D·格拉布洛夫斯基J·贝尔采钦格A·祖姆斯特格
Owner CILAG GMBH INT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap